UBS Group
SION

UBS Group’s Sionna Therapeutics SION Stock Holding History

UBS Group’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.92M Buy
147,641
+58,464
+66% +$2.23M ﹤0.01% 3883
2025
Q4 		$3.67M Buy
89,177
+42,511
+91% +$1.61M ﹤0.01% 4336
2025
Q3 		$1.37M Sell
46,666
-4,701
-9% -$102K ﹤0.01% 5299
2025
Q2 		$891K Buy
51,367
+40,221
+361% +$527K ﹤0.01% 5549
2025
Q1 		$117K Buy
+11,146
New +$182K ﹤0.01% 6934

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group's SION Position: Q1 2026 in Review

UBS Group increased its Sionna Therapeutics (SION) stake by 66% in Q1 2026, buying an estimated $2.23M and bringing the position to 147,641 shares worth $5.92M. The position accounts for ﹤0.01% of the portfolio, ranked #3883.

UBS Group first reported a position in SION in Q1 2025 and has held it in 5 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • UBS Group held 147,641 shares of Sionna Therapeutics worth $5.92M as of Q1 2026.
  • UBS Group bought 58,464 Sionna Therapeutics shares in Q1 2026, an estimated $2.23M.
  • Sionna Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3883 holding.
  • UBS Group first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.